CAS 1051375-16-6

Dolutegravir

Description:

Dolutegravir is an antiretroviral medication primarily used in the treatment of HIV infection. It belongs to the class of drugs known as integrase strand transfer inhibitors (INSTIs), which work by blocking the integrase enzyme, preventing the integration of viral DNA into the host cell's genome. Dolutegravir is characterized by its high potency, favorable pharmacokinetic profile, and a low barrier to resistance, making it effective in various treatment regimens. The substance is typically administered orally and is well-absorbed, with a long half-life that allows for once-daily dosing. It is often combined with other antiretroviral agents to enhance efficacy and reduce the risk of resistance. Dolutegravir is generally well-tolerated, though some patients may experience side effects such as insomnia, headache, or gastrointestinal disturbances. Its chemical structure includes a bicyclic core, contributing to its mechanism of action and stability. Overall, Dolutegravir represents a significant advancement in HIV therapy, improving treatment outcomes for many patients.

Formula: C₂₀H₁₉F₂N₃O₅

InChI: InChI=1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1

InChI key: InChIKey=RHWKPHLQXYSBKR-BMIGLBTASA-N

SMILES: O=C1C=2N(C[C@]3(N1[C@H](C)CCO3)[H])C=C(C(NCC4=C(F)C=C(F)C=C4)=O)C(=O)C2O

Synonyms:

• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benylamide
• 2H-Pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
• Dolutegravir free acid
• Gsk 1349572
• Gsk1349572
• S/Gsk1349572
• Soltegravir
• Tivicay
• Dolutegravir

Dolutegravir

CAS: 1051375-16-6

Dolutegravir

Purity: ≥98%

Molecular weight: 419.38g/mol

Ref: 54-BUP15005

(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide

CAS: 1051375-16-6

(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2H-Pyrido[1',2':4,5]Pyrazino[2,1-b][1,3]Oxazine-9-Carboxamide

Purity: 98%

Molecular weight: 419.38g/mol

Ref: 54-PC109099

Dolutegravir

CAS: 1051375-16-6

Formula: C₂₀H₁₉F₂N₃O₅

Color and Shape: White To Off-White Solid

Molecular weight: 419.38

Ref: 4Z-D-093001

Dolutegravir-d5

CAS: 1051375-16-6

Formula: C₂₀H₁₄D₅F₂N₃O₅

Color and Shape: Off-White Solid

Molecular weight: 424.42

Ref: 4Z-D-093002

Dolutegravir-d6

CAS: 1051375-16-6

Formula: C₂₀H₁₃D₆F₂N₃O₅

Molecular weight: 425.42

Ref: 4Z-D-093045

Dolutegravir

CAS: 1051375-16-6

Dolutegravir (GSK1349572), HIV integrase inhibitor with IC50 of 2.7 nM, partly effective against some raltegravir-resistant HIV strains.

Formula: C₂₀H₁₉F₂N₃O₅

Purity: 98.97% - 99.75%

Color and Shape: White To Pale Yellow Solid

Molecular weight: 419.38

Ref: TM-T6198

Dolutegravir

CAS: 1051375-16-6

Applications Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);

Formula: C₂₀H₁₉F₂N₃O₅

Color and Shape: White To Beige

Molecular weight: 419.38

Ref: TR-D528800

Dolutegravir-d4

Controlled Product

CAS: 1051375-16-6

Applications Isotope labelled Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.
References Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011); Garrido, C. et al.: Antiviral, Res., 90, 164 (2011); Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011);

Formula: C₂₀H₁₅D₄F₂N₃O₅

Purity: >80%

Color and Shape: Neat

Molecular weight: 423.4

Ref: TR-D528802

Dolutegravir

CAS: 1051375-16-6

Dolutegravir is an HIV-1 integrase inhibitor. Dolutegravir is used in the treatment of HIV-1 infections as it hampers the integration of the viral genome into the host DNA (Katlama, 2012). Active on a wide number of HIV-1 phenotypes, dolutegravir is highly bioavailable with an IC90 of more than 30 hours (Cottrell, 2013).

Formula: C₂₀H₁₉F₂N₃O₅

Purity: Min. 98 Area-%

Color and Shape: White Powder

Molecular weight: 419.40 g/mol

Ref: 3D-FD43372

Dolutegravir

CAS: 1051375-16-6

Purity: 98%

Molecular weight: 419.385

Ref: 10-F799806

Dolutegravir (0.1 mg/mL in Methanol)

CAS: 1051375-16-6

Formula: C₂₀H₁₉F₂N₃O₅

Color and Shape: Colourless

Molecular weight: 419.38

Ref: TR-KIT7755